期刊文献+

急性髓系白血病诱导缓解期患者下呼吸道感染病原菌分布与相关因素分析 被引量:9

Distribution of pathogenic bacteria and related factors in patients with acute myeloid leukemia complicated with lower respiratory tract infections at induced remission stage
原文传递
导出
摘要 目的分析急性髓系白血病(AML)诱导缓解期患者下呼吸道感染的病原菌分布及相关因素,为医院感染预防和控制工作提供客观依据。方法选取2015年1月-2016年12月医院收治的AML诱导缓解期患者60例为研究对象,回顾性分析患者的下呼吸道感染发生率,对感染患者分泌物标本中的病原菌分布进行检测和分析,对与AML诱导缓解期患者发生下呼吸道感染的相关因素进行回顾性研究和分析。结果 49例于诱导缓解期发生下呼吸道感染,感染率为81.7%;共检出17株病原菌,以革兰阴性菌为主,共11株占64.7%;肺部影像学特点主要以双肺病变为主,占59.2%;logistic多元回归分析结果显示,化疗方案(IA)、血红蛋白(≤60g/L)、白蛋白(≤30g/L)是发生AML诱导缓解期患者下呼吸道感染的独立危险因素(P<0.05)。结论 AML诱导缓解期患者下呼吸道感染的病原菌分布、相关因素和临床影像学特点均具有一定的特征性,临床医师应给予高度的重视和有效的干预,以提高医院感染控制效果、确保化疗疗效、改善患者的预后。 OBJECTIVE To analyze the distribution of pathogenic bacteria and related factors in patients with acute myeloid leukemia (AML) complicated with lower respiratory tract infections at induced remission stage, so as to provide basis for the prevention and control of nosocomial infections.METHODS A total of 60 patients with AML at induced remission stage from Jan.2015 to Dec.2016 were selected as the research subjects.The incidence of lower respiratory tract infections of all the included patients was retrospectively analyzed.The distribution of pathogenic bacteria in samples of lower respiratory tract secretion of patients with lower respiratory tract infection secretion samples were detected and analyzed.The related factors of occurrence of lower respiratory tract infections in patients with AML at induced remission stage were retrospectively investigated and analyzed.RESULTS There were 49 cases with lower respiratory tract infections at induced remission stage, with the infection rate of 81.7%.Totally 17 strains of pathogenic bacteria were detected, which were mainly 11 strains of gram-negative bacteria, accounting for 64.7%.The main characteristics of patients with lower respiratory tract infection were lesions in both sides, accounting for 59.2%.Logistic multivariate regression analysis showed that chemotherapy scheme (IA), hemoglobin level (≤60 g/L) and albumin (≤30 g/L) were independent risk factors for lower respiratory tract infection in patients with AML at induced remission stage (P〈0.05).CONCLUSION The distribution of pathogenic bacteria, related factors, and clinical imaging characteristics of patients with AML complicated with lower respiratory tract infections at induced remission stage have certain features.The clinicians should pay more attention and effective interventions to improve the effect of nosocomial infections, ensure the therapeutic effects of chemotherapy, and improve the prognosis of the patients.
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2017年第16期3647-3650,共4页 Chinese Journal of Nosocomiology
基金 甘肃省科技厅基金资助项目(1205TCYA023)
关键词 急性髓系白血病 诱导缓解期 下呼吸道感染 病原菌分布 相关因素 Acute myeloid leukemia Induced remission stage Lower respiratory tract infection Pathogenic bacteria distribution Related factors
  • 相关文献

参考文献8

二级参考文献51

  • 1Jianbiao Zhou,Wee-Joo Chng.Identification and targeting leukemia stem cells: The path to the cure for acute myeloid leukemia[J].World Journal of Stem Cells,2014,6(4):473-484. 被引量:9
  • 2许洪志,仲春红,徐功立,徐健,刘新.急性白血病医院感染及其危险因素的研究[J].中华医院感染学杂志,2005,15(1):37-41. 被引量:46
  • 3于海涛,胡智军.白血病肺部感染CT诊断——附96例分析[J].中华临床医学杂志,2006,7(5):40-42. 被引量:3
  • 4林斌,吴国才,李庆华,汤斌,陈群.急性白血病患者红细胞免疫粘附功能的研究[J].中国基层医药,2007,14(4):549-550. 被引量:5
  • 5Juni P,Altman DG,Egger M.Systematic reviews in health care:Assessing the quality of controlled clinical trials[J].BMJ,2001,323:42-46.
  • 6Beksac M,Arslan O,Koc H,et al.Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia[J].Med Oncol,1998,15:183-190.
  • 7Berman E,Heller G,Santorsa J,et al.Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia[J].Blood,1991,77:1666-1674.
  • 8Mandelli F,Vignetti M,Suciu S,et al.Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia:the EORTC and GIMEMA Groups Study AML-10[J].J Clin Oncol,2009,27:5397-5403.
  • 9Ohtake S,Miyawaki S,Fujita H,et al.Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia:the JALSG AML201Study[J].Blood,2011,117:2358-2365.
  • 10Reiffers J,Huguet F,Stoppa AM,et al.A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55to 75[J].Leukemia,1996,10:389-395.

共引文献47

同被引文献84

引证文献9

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部